logo
Photos show Swiss glaciers' uncertain future as 'ambassadors of climate change'

Photos show Swiss glaciers' uncertain future as 'ambassadors of climate change'

Yahoo8 hours ago

RHONE GLACIER, Switzerland (AP) — Drip, drip. Trickle, trickle.
That's the sound of water seeping from a sunbaked and slushy Swiss glacier that geoscientists are monitoring for signs of continued retreat by the majestic masses of ice under the heat of global warming.
In recent years, glaciologists like Matthias Huss of the Federal Institute of Technology in Zurich, known as ETHZ, and others have turned to dramatic measures to help protect glaciers like the Rhone Glacier, which feeds into the river of the same name that runs through Switzerland and France.
One of those desperate steps involves using giant sheets to cover the ice like blankets to slow the melt.
Switzerland is continental Europe's glacier capital, with some 1,400 that provide drinking water, irrigation for farmland in many parts of Europe including French wine country, and hydropower that generates most of the country's electricity.
The number has been dwindling. The Alpine country has already lost up to 1,000 small glaciers, and the bigger ones are increasingly at risk.
Drilling into glaciers to track what's happening inside
Huss hosted The Associated Press for a visit to the sprawling glacier this month, as he carried out his first monitoring mission as summer temperatures accelerate the thaw. Under normal conditions, glaciers can regenerate in the winter, but climate change is threatening that.
'I always say glaciers are the ambassadors of climate change because they can spread this message in a very understandable way," Huss said. "They also cause good feelings because glaciers are beautiful. We know them from our holidays.'
The vast expanse of blue, gray and white ice is riddled with cracks and grooves, and Huss says his teams at the Swiss GLAMOS glacier monitoring group have spotted a new phenomenon in Switzerland: holes appearing beneath the surface that at times widen so much that the ice above collapses.
Huss uses an auger to bore into the ice, sending frosty chips upward as if from a gushing fountain. It's part of a process that involves using stakes and poles to track ice loss from melting.
A better understanding of glacier melt
Huss monitors melting not just at the top but also from the base of glaciers.
'Normally glaciers melt from the top because of the warm air, because of their radiation from the sun. But in recent years we realized at several sites that there is a substantive melt from the bottom,' Huss said. 'If there are some channels in the ice through which air is circulating, this can excavate big holes under the ice.'
The Alps were covered with ice 20,000 years ago, but no more. It's the same story elsewhere. Experts have warned that some two-thirds of the world's glaciers are set to disappear by the end of this century
Huss says only humans can help save them.
'It's difficult to save this very glacier because it could only be saved — or at least made to retreat slower — by bringing down CO2 emissions," he said. 'But everybody can contribute on their own to reduce CO2 emissions as far as possible."
'This will not help this glacier immediately, but it will help all glaciers in the long range,' he added. "This is the important thing that we should think of if we see this melting ice and this big retreat — that it's time to act now.'
A glacier gives way, and a village is destroyed
The concerns about Switzerland's glaciers intensified recently after the southwestern village of Blatten, tucked near the Birch Glacier, was largely destroyed by a slide of rock and glacier ice in May. The village had been evacuated ahead of the slide, which covered dozens of homes and buildings and left just a few rooftops visible.
A review of data showed that the Birch Glacier was a rarity in that it has been advancing while most glaciers have been receding. And its advance had been increasing in recent years, to the point that it was flowing at about 10 meters (about 30 feet) per day shortly before the collapse — a rate Huss called 'completely unsustainable.'
Huss said the landslide was triggered by rocks piling onto the glacier, though he also called Birch's advance a 'precursor."
The main takeaway from the Birch Glacier collapse, Huss says, is that 'unexpected things happen.'
'If you ask me, like three weeks ago, nobody would have guessed that the whole village is going to be destroyed,' he said. "I think this is the main lesson to be learned, that we need to be prepared.'
___
AP journalist Jamey Keaten in Geneva contributed to this report.
___
The Associated Press' climate and environmental coverage receives financial support from multiple private foundations. AP is solely responsible for all content. Find AP's standards for working with philanthropies, a list of supporters and funded coverage areas at AP.org.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The World Is Warming Up. And It's Happening Faster.
The World Is Warming Up. And It's Happening Faster.

New York Times

time3 hours ago

  • New York Times

The World Is Warming Up. And It's Happening Faster.

Summer started barely a week ago, and already the United States has been smothered in a record-breaking 'heat dome.' Alaska saw its first-ever heat advisory this month. And all of this comes on the heels of 2024, the hottest calendar year in recorded history. The world is getting hotter, faster. A report published last week found that human-caused global warming is now increasing by 0.27 degrees Celsius per decade. That rate was recorded at 0.2 degrees in the 1970s, and has been growing since. This doesn't surprise scientists who have been crunching the numbers. For years, measurements have followed predictions that the rate of warming in the atmosphere would speed up. But now, patterns that have been evident in charts and graphs are starting to become a bigger part of people's daily lives. 'Each additional fractional degree of warming brings about a relatively larger increase in atmospheric extremes, like extreme downpours and severe droughts and wildfires,' said Daniel Swain, a climate scientist at the University of California. While this aligns with scientific predictions of how climate change can intensify such events, the increase in severity may feel sudden to people who experience them. 'Back when we had lesser levels of warming, that relationship was a little bit less dramatic,' Dr. Swain said. 'There is growing evidence that the most extreme extremes probably will increase faster and to a greater extent than we used to think was the case,' he added. Want all of The Times? Subscribe.

CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline
CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline

Yahoo

time7 hours ago

  • Yahoo

CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline

-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% in LDL, with a well-tolerated safety profile- -Complete Phase 1 data presentation for CTX310 anticipated at a medical meeting in the second half of 2025- -Data update for CTX320™, targeting the LPA gene, now expected in the first half of 2026- -Preclinical in vivo cardiovascular program CTX340™ advancing toward IND / CTA filings targeting refractory hypertension- ZUG, Switzerland and BOSTON, June 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases today announced updates across its in vivo cardiovascular disease programs. These include new data for CTX310™, targeting ANGPTL3, as well as continued progress on CTX320™, targeting the LPA gene, and CTX340™, targeting the AGT gene. 'CRISPR Therapeutics remains focused on executing against our strategic priorities and advancing our portfolio of innovative therapies,' said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. 'The additional data from our ongoing Phase 1 clinical trial for CTX310 reinforces the potential of our platform to transform the treatment of serious cardiovascular diseases. We are progressing with our dose-finding study and expect to share complete data at a medical meeting in the second half of this year. For CTX320, we are continuing our dose-finding study and anticipate sharing data in the first half of 2026, reflecting a strategic decision to incorporate emerging insights from the evolving Lp(a) treatment landscape.' CTX310, targeting CTX310 targets ANGPTL3, a gene that encodes for key protein involved in the regulation of low-density lipoprotein (LDL) and triglyceride (TG) levels – both of which are recognized risk factors for atherosclerotic heart disease (ASCVD). Loss-of-function mutations in ANGPTL3 are associated with significantly reduced levels of LDL and TGs, as well as reduced risk of ASCVD, without known adverse health effects. More than 40 million patients in the U.S. alone are affected by elevated LDL, severely elevated TG or both – representing a significant unmet need and a large addressable population. CTX310 is initially focused on high-risk patients with the greatest unmet medical need and limited effective treatment options. CTX310 is in an ongoing Phase 1 first-in-human clinical trial targeting ANGPTL3 in four patient groups: homozygous familial hypercholesterolemia (HoFH), severe hypertriglyceridemia (sHTG), heterozygous familial hypercholesterolemia (HeFH), or mixed dyslipidemias (MDL). Eligible participants have levels of TG >300 mg/dL and/or LDL-C >100 mg/dL (or >70 mg/dL for subjects with ASCVD). Both LDL and TG are validated surrogate endpoints accepted by regulatory agencies. These new results build upon previously disclosed results from the first 10 patients across the first four cohorts (lean body weight-based doses of DL1 [0.1 mg/kg], DL2 [0.3 mg/kg], DL3 [0.6 mg/kg] and DL4 [0.8 mg/kg]) with at least 30 days of follow-up for each participant. As dose-range finding continues, data to date demonstrate peak reductions of up to 82% in TG and LDL reductions of up to 86% at DL4 without any clinically significant changes in liver enzymes and a safety and tolerability profile consistent with previous findings. The Company anticipates presenting the complete Phase 1 data for CTX310 at a medical meeting in the second half of 2025. CTX320™, targeting CTX320 is in an ongoing Phase 1 clinical trial targeting the LPA gene in patients with elevated lipoprotein(a) [Lp(a)], a genetically determined risk factor associated with increased incidence of major adverse cardiovascular events (MACE). Elevated Lp(a) levels affect up to 20% of the global population and remains unaddressed by current therapies. The Phase 1 trial is enrolling patients and dose-finding is ongoing. An update is now expected in the first half of 2026, reflecting a strategic decision to incorporate emerging insights from the evolving Lp(a) landscape. CTX340, targeting angiotensinogen (AGT) CRISPR Therapeutics is also advancing its preclinical in vivo cardiovascular program CTX340, targeting angiotensinogen (AGT) for the treatment of refractory hypertension. CTX340 is currently progressing through IND/CTA-enabling studies. About ProgramsCRISPR Therapeutics has established a proprietary lipid nanoparticle (LNP) platform for the delivery of CRISPR/Cas9 to the liver. The Company's in vivo portfolio includes its lead investigational programs, CTX310 (directed towards angiopoietin-related protein 3 (ANGPTL3)) and CTX320 (directed towards LPA, the gene encoding apolipoprotein(a) (apo(a)), a major component of lipoprotein(a) [Lp(a)]). Both are validated therapeutic targets for cardiovascular disease. CTX310 and CTX320 are in ongoing clinical trials in patients with heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, mixed dyslipidemias, or severe hypertriglyceridemia, and in patients with elevated lipoprotein(a), respectively. In addition, the Company's research and preclinical development candidates include CTX340 and CTX450™, targeting angiotensinogen (AGT) for refractory hypertension and 5'-aminolevulinate synthase 1 (ALAS1) for acute hepatic porphyria (AHP), respectively. About CRISPR TherapeuticsSince its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit CRISPR THERAPEUTICS® standard character mark and design logo CTX310™, CTX320™, CTX340™ and CTX450™ are trademarks and registered trademarks of CRISPR Therapeutics AG. CASGEVY® and the CASGEVY logo are registered trademarks of Vertex Pharmaceuticals Incorporated. All other trademarks and registered trademarks are the property of their respective owners. CRISPR Special Note Regarding Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements made by Dr. Kulkarni in this press release, as well as regarding any or all of the following: (i) CRISPR Therapeutics preclinical studies, clinical trials and pipeline products and programs, including, without limitation, status of such studies and trials (including guidance) and expectations regarding data, safety and efficacy generally; (ii) data included in this press release, as well as the ability to use data from ongoing and planned clinical trials for the design and initiation of further clinical trials; (iii) regulatory submissions and authorizations, including related timelines; and (iv) the therapeutic value, development, and commercial potential of gene editing and delivery technologies and therapies, including CRISPR/Cas9. Risks that contribute to the uncertain nature of the forward-looking statements include, without limitation, the risks and uncertainties discussed under the heading 'Risk Factors' in its most recent annual report on Form 10-K and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law. This press release also contains information regarding our industry, our business and the markets for certain of our product candidates, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Unless otherwise expressly stated, we obtained this industry, business, market and other data from market research firms and other third parties, including medical publications, government data and similar sources. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. This press release discusses CRISPR/Cas9 gene editing investigational therapies and is not intended to convey conclusions about efficacy or safety as to those investigational therapies or uses of such investigational therapies. There is no guarantee that any investigational therapy will successfully complete clinical development or gain approval from applicable regulatory authorities. Investor Contact:+1-617-307-7503ir@ Media Contact:+1-617-315-4493media@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Photos show Swiss glaciers' uncertain future as 'ambassadors of climate change'
Photos show Swiss glaciers' uncertain future as 'ambassadors of climate change'

Yahoo

time8 hours ago

  • Yahoo

Photos show Swiss glaciers' uncertain future as 'ambassadors of climate change'

RHONE GLACIER, Switzerland (AP) — Drip, drip. Trickle, trickle. That's the sound of water seeping from a sunbaked and slushy Swiss glacier that geoscientists are monitoring for signs of continued retreat by the majestic masses of ice under the heat of global warming. In recent years, glaciologists like Matthias Huss of the Federal Institute of Technology in Zurich, known as ETHZ, and others have turned to dramatic measures to help protect glaciers like the Rhone Glacier, which feeds into the river of the same name that runs through Switzerland and France. One of those desperate steps involves using giant sheets to cover the ice like blankets to slow the melt. Switzerland is continental Europe's glacier capital, with some 1,400 that provide drinking water, irrigation for farmland in many parts of Europe including French wine country, and hydropower that generates most of the country's electricity. The number has been dwindling. The Alpine country has already lost up to 1,000 small glaciers, and the bigger ones are increasingly at risk. Drilling into glaciers to track what's happening inside Huss hosted The Associated Press for a visit to the sprawling glacier this month, as he carried out his first monitoring mission as summer temperatures accelerate the thaw. Under normal conditions, glaciers can regenerate in the winter, but climate change is threatening that. 'I always say glaciers are the ambassadors of climate change because they can spread this message in a very understandable way," Huss said. "They also cause good feelings because glaciers are beautiful. We know them from our holidays.' The vast expanse of blue, gray and white ice is riddled with cracks and grooves, and Huss says his teams at the Swiss GLAMOS glacier monitoring group have spotted a new phenomenon in Switzerland: holes appearing beneath the surface that at times widen so much that the ice above collapses. Huss uses an auger to bore into the ice, sending frosty chips upward as if from a gushing fountain. It's part of a process that involves using stakes and poles to track ice loss from melting. A better understanding of glacier melt Huss monitors melting not just at the top but also from the base of glaciers. 'Normally glaciers melt from the top because of the warm air, because of their radiation from the sun. But in recent years we realized at several sites that there is a substantive melt from the bottom,' Huss said. 'If there are some channels in the ice through which air is circulating, this can excavate big holes under the ice.' The Alps were covered with ice 20,000 years ago, but no more. It's the same story elsewhere. Experts have warned that some two-thirds of the world's glaciers are set to disappear by the end of this century Huss says only humans can help save them. 'It's difficult to save this very glacier because it could only be saved — or at least made to retreat slower — by bringing down CO2 emissions," he said. 'But everybody can contribute on their own to reduce CO2 emissions as far as possible." 'This will not help this glacier immediately, but it will help all glaciers in the long range,' he added. "This is the important thing that we should think of if we see this melting ice and this big retreat — that it's time to act now.' A glacier gives way, and a village is destroyed The concerns about Switzerland's glaciers intensified recently after the southwestern village of Blatten, tucked near the Birch Glacier, was largely destroyed by a slide of rock and glacier ice in May. The village had been evacuated ahead of the slide, which covered dozens of homes and buildings and left just a few rooftops visible. A review of data showed that the Birch Glacier was a rarity in that it has been advancing while most glaciers have been receding. And its advance had been increasing in recent years, to the point that it was flowing at about 10 meters (about 30 feet) per day shortly before the collapse — a rate Huss called 'completely unsustainable.' Huss said the landslide was triggered by rocks piling onto the glacier, though he also called Birch's advance a 'precursor." The main takeaway from the Birch Glacier collapse, Huss says, is that 'unexpected things happen.' 'If you ask me, like three weeks ago, nobody would have guessed that the whole village is going to be destroyed,' he said. "I think this is the main lesson to be learned, that we need to be prepared.' ___ AP journalist Jamey Keaten in Geneva contributed to this report. ___ The Associated Press' climate and environmental coverage receives financial support from multiple private foundations. AP is solely responsible for all content. Find AP's standards for working with philanthropies, a list of supporters and funded coverage areas at

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store